Clinical Trial Update: Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B [Phase 3]

View source ↗

Summary

Phase 3 trial comparing on-demand BeneFIX versus a prophylaxis regimen in subjects with moderately severe to severe Hemophilia B; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BeneFIX (recombinant coagulation factor IX concentrate)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2015-05-04